PURPOSE: Quality in cancer care is an issue that has come to the forefront over the past decade. Although the American Society of Clinical Oncology has developed extensive quality metrics and goals, such as limiting chemotherapy being provided within the last 14 days of a patient's life, there are no similar quality metrics, and few data, in the field of radiation oncology. METHODS: In this study, morbidity and mortality records from 2008 to 2011 were reviewed for patients at Indiana University who received radiation therapy (RT) within 30 days of death; 63 patients met those criteria. RESULTS: Analysis showed that 22.2% of patients had Karnofsky Performance Status Scale scores >80, whereas 66.7% of patients had scores < 60. Just over half of patients (52%) were still on treatment at death, and more than half of patients (54%) had completed less than half of their original RT plans. Six patients had their final treatments on the days of their deaths, and another 43 patients had their last treatments within 10 days of death. Forty-eight percent of patients received RT for less than one-fifth of their final month of life and 21% for more than half of their last month alive. CONCLUSIONS: These data are valuable in ongoing discussions of RT use at the end of life, especially as related to hospice underutilization.
PURPOSE: Quality in cancer care is an issue that has come to the forefront over the past decade. Although the American Society of Clinical Oncology has developed extensive quality metrics and goals, such as limiting chemotherapy being provided within the last 14 days of a patient's life, there are no similar quality metrics, and few data, in the field of radiation oncology. METHODS: In this study, morbidity and mortality records from 2008 to 2011 were reviewed for patients at Indiana University who received radiation therapy (RT) within 30 days of death; 63 patients met those criteria. RESULTS: Analysis showed that 22.2% of patients had Karnofsky Performance Status Scale scores >80, whereas 66.7% of patients had scores < 60. Just over half of patients (52%) were still on treatment at death, and more than half of patients (54%) had completed less than half of their original RT plans. Six patients had their final treatments on the days of their deaths, and another 43 patients had their last treatments within 10 days of death. Forty-eight percent of patients received RT for less than one-fifth of their final month of life and 21% for more than half of their last month alive. CONCLUSIONS: These data are valuable in ongoing discussions of RT use at the end of life, especially as related to hospice underutilization.
Authors: Davide Gori; Rajendra Dulal; Douglas W Blayney; James D Brooks; Maria P Fantini; Kathryn M McDonald; Tina Hernandez-Boussard Journal: Jt Comm J Qual Patient Saf Date: 2018-09-18
Authors: Siran M Koroukian; Nicholas K Schiltz; David F Warner; Charles W Given; Mark Schluchter; Cynthia Owusu; Nathan A Berger Journal: J Geriatr Oncol Date: 2016-10-28 Impact factor: 3.599
Authors: Petra Grendarova; Aynharan Sinnarajah; Theresa Trotter; Cynthia Card; Jackson S Y Wu Journal: Support Care Cancer Date: 2015-03-07 Impact factor: 3.603
Authors: Xhyljeta Luta; Maud Maessen; Matthias Egger; Andreas E Stuck; David Goodman; Kerri M Clough-Gorr Journal: PLoS One Date: 2015-04-14 Impact factor: 3.240
Authors: Sebastian M Christ; Markus Schettle; Annina Seiler; Matthias Guckenberger; David Blum; Nicolaus Andratschke; Caroline Hertler Journal: Clin Transl Radiat Oncol Date: 2021-07-04